187 related articles for article (PubMed ID: 33931953)
41. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
42. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Ogura J; Kuwayama K; Sasaki S; Kaneko C; Koizumi T; Yabe K; Tsujimoto T; Takeno R; Takaya A; Kobayashi M; Yamaguchi H; Iseki K
Biochem Pharmacol; 2015 Sep; 97(1):89-98. PubMed ID: 26119820
[TBL] [Abstract][Full Text] [Related]
43. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
44. Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.
Ng DY; Stocker SL; Graham GG; Williams KM; Day RO
Eur J Clin Pharmacol; 2011 Jul; 67(7):709-13. PubMed ID: 21181139
[TBL] [Abstract][Full Text] [Related]
45. Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.
Woodward OM; Tukaye DN; Cui J; Greenwell P; Constantoulakis LM; Parker BS; Rao A; Köttgen M; Maloney PC; Guggino WB
Proc Natl Acad Sci U S A; 2013 Mar; 110(13):5223-8. PubMed ID: 23493553
[TBL] [Abstract][Full Text] [Related]
46. Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers.
Lu XF; Zhou Y; Bi KS; Chen XH
Xenobiotica; 2016 Sep; 46(9):841-9. PubMed ID: 26744986
[TBL] [Abstract][Full Text] [Related]
47. The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
Mills PC; Dunnett M; Smith NC
J Vet Pharmacol Ther; 1995 Dec; 18(6):451-6. PubMed ID: 8789699
[TBL] [Abstract][Full Text] [Related]
48. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
49. No association between ATP-binding cassette transporter G2 rs2231142 (Q141K) and urate-lowering response to febuxostat.
Stamp LK; Topless R; Miner JN; Dalbeth N; Merriman T
Rheumatology (Oxford); 2019 Mar; 58(3):547-548. PubMed ID: 30597115
[No Abstract] [Full Text] [Related]
50. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
51. Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis.
Wallace MC; Roberts RL; Nanavati P; Miner JN; Dalbeth N; Topless R; Merriman TR; Stamp LK
Rheumatology (Oxford); 2018 Apr; 57(4):656-660. PubMed ID: 29342288
[TBL] [Abstract][Full Text] [Related]
52. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol.
Moriwaki Y; Yamamoto T; Tsutsumi Z; Takahashi S; Hada T
Metabolism; 2002 Jul; 51(7):893-5. PubMed ID: 12077737
[TBL] [Abstract][Full Text] [Related]
53. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
[TBL] [Abstract][Full Text] [Related]
55. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP;
J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913
[TBL] [Abstract][Full Text] [Related]
56. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
57. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
58. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
59. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
[TBL] [Abstract][Full Text] [Related]
60. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.
Hosomi A; Nakanishi T; Fujita T; Tamai I
PLoS One; 2012; 7(2):e30456. PubMed ID: 22348008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
